NovaScan

NovaScan, founded in 2003, is a biotechnology and healthcare company based in the United States. The company's slogan "Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results" signifies its novel approach to cancer diagnosis. NovaScan has developed a clinical-stage oncology diagnostic platform for real-time cancer detection and stratification with a low-cost, single-use device. Clinical trials and commercialization efforts are underway for use in lung, breast, skin, GI, and pancreatic cancers, offering the ability to detect malignancy without tissue acquisition. The revolutionary use of the Cole Relaxation Frequency has demonstrated highly accurate results in clinical trials and will provide ex vivo and in vivo detection at the point-of-care, during procedures, and post-procedural pathology. The significant advantages of the platform, including improved patient outcomes, increased physician economies, and reductions in the cost of care, make it an attractive investment opportunity. Notably, NovaScan received a significant $3.00M Convertible Note investment at 22 January 2021 from investors Green Park & Golf Ventures, Stateline Angels, Harvard Business School Angels Chicago, and BioPacific Investors. This latest investment underscores the potential of NovaScan's innovative diagnostic platform.